【ChiCTR1900028604】Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment
ChiCTR1900028604
尚未开始
/
/
/
2019-12-28
/
/
青光眼
Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment
Clinical Observation of Combined Acupuncture Points with Deep Puncture at the Acupoint Jingming BL1 for Glaucoma Treatment
47100
1. To assess the effectiveness of deep puncture treatment in lowering the IOP in POAG patients. 2. To assess the effectiveness of deep puncture treatment in improving visual acuity in POAG patients. 3. To assess the safety of deep puncture at acupoint Jingming BL1 reaching a depth of 40mm from an angle of 85 degree.
单臂
回顾性研究
Selection of participants is done according to inclusion and exclusion criteria by principal investigator.
No
Self-funded
/
25
/
2020-02-03
2020-06-30
/
Study participants will be those who are: 1. of either gender; 2. > 18 and < 80 years of age; 3. diagnosed as POAG according to the diagnostic criteria of POAG used in current ophthalmology practice; 4. not legally blind by the official definition of having central visual acuity of 20/200 or less in the better eye with corrective lenses, and /or a visual field of 20 degrees or less in the better eye; 5. never before treated with deep acupuncture at acupoint Jingming BL1 for glaucoma.；
请登录查看Exclusion criteria will be as follows: 1. Participants with cardiovascular, kidney, liver, or hematopoietic system diseases, mental health disorders, cancer or other severe diseases for whom acupuncture may be inappropriate or unsafe; 2. Participants with other diseases that could interfere with acupuncture treatment, e.g., clotting disorders or leukopenia, active skin infection, epilepsy, or on anticoagulant therapy (aspirin, warfarin etc); 3. Participants with a pacemaker, metal allergy, or severe fear of needles; 4. Women who are pregnant or lactating; 5. Participants who have difficulties in attending the trial (e.g. paralysis, cancer, dementia, drug addiction, time constraints, surgical operation).；
请登录查看马来西亚雅兰大学
43000
马来西亚雅兰大学的其他临床试验
马来西亚雅兰大学的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验（FIH）成功开展，国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药：超长效靶向TSLP抗体哮喘二期临床取得阳性结果，三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 20 8
-
摩熵咨询 20 11
-
摩熵咨询 34 56
-
颁布机构：国家药品监督管理局 2026-09-10
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-09-28
-
2026-09-26
-
2026-09-26
-
摩熵咨询 35 71
-
摩熵咨询 28 60
-
摩熵咨询 34 42
-
颁布机构：国家市场监督管理总局 2026-09-18
-
颁布机构：国家市场监督管理总局 2026-09-17
-
颁布机构：国家市场监督管理总局 2026-08-10